Skip to main content
Top
Published in: BMC Gastroenterology 1/2015

Open Access 01-12-2015 | Research article

Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis

Authors: Rohan Chaminda Siriwardana, Madunil Anuk Niriella, Anuradha Supun Dassanayake, Chandika Anuradha Habarakada Liyanage, Angappulige Upasena, Chandra Sirigampala, Hithanadura Janaka de Silva

Published in: BMC Gastroenterology | Issue 1/2015

Login to get access

Abstract

Background

Transarterial-chemo-embolization (TACE) is used for palliation of unresectable hepatocellular carcinoma (HCC). We studied the tolerability of TACE in a cohort of patients with NASH and alcoholic cirrhosis related HCC.

Methods

Of 290 patients with HCC (July 2011 - December 2014), 84 underwent TACE. They were monitored for post-TACE complications: postembolization fever (PEF), nausea and vomiting (NV), abdominal pain, infection, acute hepatic decompensation (AHD) and acute kidney injury (AKI).

Results

84 patients [90.5 % males, 89.2 % cirrhotics, 89.2 % nodular HCC, median age 63 (34–84) years] underwent 111 TACE sessions. All were Child class A [69.4 % sessions (n = 77)] or B; ascites and portal vein invasion was present in 18 (16.2 %) and 15 (13.6 %), respectively.
42 (38.2 %) TACE procedures resulted in complications [PEF 28 (25.2 %), NV 4 (3.6 %), abdominal pain 9 (8.1 %), infection 7 (6.3 %), AHD 13 (11.7 %), AKI 3 (2.7 %)]. There were no immediate post-TACE deaths.
On univariate analysis elevated serum bilirubin (p = 0.046) and low serum albumin (p = 0.035) predicted PEF while low serum albumin (p = 0.021) and low platelet counts (p = 0.041) predicted AHD. In the multivariate model, factors with p < 0.200 on univariate analysis and factors derived from the previous literature were considered covariates. Female gender (p = 0.029, OR = 1.412), ascites (p = 0.030, OR = 1.212), elevated serum bilirubin (p = 0.007, OR = 4.357) and large tumour size (p = 0.036, OR = 3.603) were independent risk factors for PEF. Tumour diameter >5 cm (p = 0.049, OR = 2.410) and elevated serum bilirubin (p = 0.036, OR = 1.517) predicted AHD.

Conclusion

In NASH and alcoholic cirrhosis related HCC patients pre-procedure serum bilirubin, ascites, tumour size and female gender predicted PEF post-TACE. Tumours larger 5 cm with elevated bilirubin predicted AHD post-TACE.
Literature
1.
go back to reference El-Serag HB. Hepatocellular Carcinoma. Massachusetts Medical Society. N Engl J Med. 2011;365(12):1118–27.CrossRefPubMed El-Serag HB. Hepatocellular Carcinoma. Massachusetts Medical Society. N Engl J Med. 2011;365(12):1118–27.CrossRefPubMed
2.
go back to reference Siriwardana RC, Niriella MA, Liyanage CAH, Wijesuriya SR, Gunathilaka B, Dassanayake AS, et al. Cryptogenic cirrhosis is the leading cause for listing for liver transplantation in Sri Lanka. Indian J Gastroenterol. 2013;32(6):397–9.CrossRefPubMed Siriwardana RC, Niriella MA, Liyanage CAH, Wijesuriya SR, Gunathilaka B, Dassanayake AS, et al. Cryptogenic cirrhosis is the leading cause for listing for liver transplantation in Sri Lanka. Indian J Gastroenterol. 2013;32(6):397–9.CrossRefPubMed
3.
go back to reference Lo C-M, Ngan H, Tso W-K, Liu C-L, Lam C-M, Poon RT-P, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology WB Saunders. 2002;35(5):1164–71.CrossRef Lo C-M, Ngan H, Tso W-K, Liu C-L, Lam C-M, Poon RT-P, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology WB Saunders. 2002;35(5):1164–71.CrossRef
4.
go back to reference Min YW, Kim J, Kim S, Sung YK, Lee JH, Gwak G-Y, et al. isk factors and a predictive model for acute hepatic failure after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Liver Int. 2013;33:197–202.CrossRefPubMed Min YW, Kim J, Kim S, Sung YK, Lee JH, Gwak G-Y, et al. isk factors and a predictive model for acute hepatic failure after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Liver Int. 2013;33:197–202.CrossRefPubMed
5.
go back to reference Li C-P, Chao Y, Chen L-T, Lee R-C, Lee W-P, Yuan J-N, et al. Fever after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. Scand J Gastroenterol. 2008;43(8):992–9.CrossRefPubMed Li C-P, Chao Y, Chen L-T, Lee R-C, Lee W-P, Yuan J-N, et al. Fever after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. Scand J Gastroenterol. 2008;43(8):992–9.CrossRefPubMed
6.
go back to reference Chan AO, Yuen M-F, Hui C-K, Tso W-K, Lai C-L. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer. 2002;94(6):1747–52.CrossRefPubMed Chan AO, Yuen M-F, Hui C-K, Tso W-K, Lai C-L. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer. 2002;94(6):1747–52.CrossRefPubMed
7.
go back to reference Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2015;362(9399):1907–17.CrossRef Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2015;362(9399):1907–17.CrossRef
8.
go back to reference Zhou C, Wang R, Ding Y, Du L, Hou C, Lu D, et al. Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma. Int J Clin Exp Pathol. 2014;7(5):2579–86.PubMedPubMedCentral Zhou C, Wang R, Ding Y, Du L, Hou C, Lu D, et al. Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma. Int J Clin Exp Pathol. 2014;7(5):2579–86.PubMedPubMedCentral
9.
go back to reference Jun CH, Ki HS, Lee HK, Park KJ, Park SY, Cho SB, et al. Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma. World J Gastroenterol. 2013;19(2):284–9.CrossRefPubMedPubMedCentral Jun CH, Ki HS, Lee HK, Park KJ, Park SY, Cho SB, et al. Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma. World J Gastroenterol. 2013;19(2):284–9.CrossRefPubMedPubMedCentral
10.
go back to reference Huang Y-S, Chiang J-H, Wu J-C, Chang F-Y, Lee S-D. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. Am J Gastroenterol. 2002;97(5):1223–7.CrossRefPubMed Huang Y-S, Chiang J-H, Wu J-C, Chang F-Y, Lee S-D. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. Am J Gastroenterol. 2002;97(5):1223–7.CrossRefPubMed
11.
go back to reference Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective Cohort Study of Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma in 8510 Patients. Gastroenterology. 2015;131(2):461–9.CrossRef Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective Cohort Study of Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma in 8510 Patients. Gastroenterology. 2015;131(2):461–9.CrossRef
12.
go back to reference Chen C, Tsang Y-M, Hsueh P-R, Huang G-T, Yang P-M, Sheu J-C, et al. Bacterial Infections Associated with Hepatic Arteriography and Transarterial Embolization for Hepatocellular Carcinoma: A Prospective Study. Clin Infect Dis. 1999;29(1):161–6.CrossRefPubMed Chen C, Tsang Y-M, Hsueh P-R, Huang G-T, Yang P-M, Sheu J-C, et al. Bacterial Infections Associated with Hepatic Arteriography and Transarterial Embolization for Hepatocellular Carcinoma: A Prospective Study. Clin Infect Dis. 1999;29(1):161–6.CrossRefPubMed
13.
go back to reference Wigmore SJ, Redhead DN, Thomson BNJ, Currie EJ, Parks RW, Madhavan KK, et al. Postchemoembolisation syndrome--tumour necrosis or hepatocyte injury? Br J Cancer. 2003;89:1423–7.CrossRefPubMedPubMedCentral Wigmore SJ, Redhead DN, Thomson BNJ, Currie EJ, Parks RW, Madhavan KK, et al. Postchemoembolisation syndrome--tumour necrosis or hepatocyte injury? Br J Cancer. 2003;89:1423–7.CrossRefPubMedPubMedCentral
14.
go back to reference Khan KN, Nakata K, Kusumoto Y, Shima M, Ishii N, Koji T, et al. Evaluation of Nontumorous Tissue Damage by Transcatheter Arterial Embolization for Hepatocellular Carcinoma. Cancer Res. 1991;51(20):5667–71.PubMed Khan KN, Nakata K, Kusumoto Y, Shima M, Ishii N, Koji T, et al. Evaluation of Nontumorous Tissue Damage by Transcatheter Arterial Embolization for Hepatocellular Carcinoma. Cancer Res. 1991;51(20):5667–71.PubMed
Metadata
Title
Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis
Authors
Rohan Chaminda Siriwardana
Madunil Anuk Niriella
Anuradha Supun Dassanayake
Chandika Anuradha Habarakada Liyanage
Angappulige Upasena
Chandra Sirigampala
Hithanadura Janaka de Silva
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2015
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-015-0329-8

Other articles of this Issue 1/2015

BMC Gastroenterology 1/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.